Phase 1 Trial of Adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) Study Group

BACKGROUND: Patients with primary focal segmental glomerulosclerosis (FSGS) resistant to current treatment regimens are at high risk of progression to end stage kidney disease. Antifibrotic agents, such as tumor necrosis factor α (TNF-α) antagonists, are a promising strategy to slow or halt the decl...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Joy, Melanie S., Gipson, Debbie S., Powell, Leslie, MacHardy, Jacqueline, Jennette, J. Charles, Vento, Suzanne, Pan, Cynthia, Savin, Virginia, Eddy, Allison, Fogo, Agnes B., Kopp, Jeffrey B., Cattran, Daniel, Trachtman, Howard
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2009
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2804955/
https://ncbi.nlm.nih.gov/pubmed/19932542
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1053/j.ajkd.2009.08.019
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items